CLVT

AI MemoPost-earnings T+1

Clarivate

As of 2026-11-04/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-11-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q4 recurring-growth and cash-flow delivery • 2026-12-31

Base target: $2 / p=45% prob

Biggest risk

Continuing-operations revenue fell 9.2% in Q3, transactional revenue remained weak, and nine-month free cash flow declined to $233.1 million from $276.1 million. Debt outstanding was $4.18 billion at September 30. The reported GAAP net loss included a non-cash impairment. [#SEC-8K-2026-11-03]

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Q3 organic ACV grew 1.8%, organic recurring revenue grew 1.3%, and the completed sale narrows management's focus to two segments. Meeting Q4 growth and cash-flow guidance could support a rerating. [#SEC-8K-2026-11-03]

Research note

Recommendation

—

Confidence

medium

As of

2026-11-04

Base target

p=45%

Bull target

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 earnings reaction and revised outlook
Prove growth and deleveraging after the portfolio sale
Q3 organic ACV grew 1.8%, organic recurring revenue grew 1.3%, and the completed sale narrows management's focus to two segments.

BearKey bullets

A 25.9% post-results close-to-close gain increases reversal risk.
https://stockanalysis.com/stocks/clvt/history/
High debt and lower year-to-date free cash flow leave deleveraging dependent on execution.

WatchKey bullets

Q4 recurring-growth and cash-flow delivery

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $2 (p=45%)

Target spread vs base: +33% / -31%

Scenario probabilities

Bull Target: $3 (p=30%)Base Target: $2 (p=45%)Bear Target: $1 (p=25%)

Commentary

The initial premarket reaction was negative in coverage focused on the revenue miss, but shares finished November 3 up 25.9%. https://www.investing.com/news/stock-market-news/why-is-clarivate-stock-sliding-today-93CH-4994928 https://stockanalysis.com/stocks/clvt/history/ The company release supports an adjusted-EPS beat and improving recurring metrics, but the divestiture complicates revenue-surprise comparisons. No confirmed post-print analyst revision is available at this T+1 checkpoint; social, options, short-interest and employee measures were not supplied, so the zero placeholders above are not observations.

As of 2026-11-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 earnings reaction and revised outlook
Prove growth and deleveraging after the portfolio sale

Scenarios

Bull Target (Scenario probability)

$3 / p=30% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Analysis 2026-11-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Q4 recurring-growth and cash-flow delivery
Management's Q4 outlook calls for 2.0%–2.5% recurring organic revenue growth, 1.75%–2.25% organic ACV growth and $85 million–$105 million of free cash flow. Delivery would help validate the post-divestiture business; weaker transactional revenue or cash conversion would challenge it. The date is the Q4 period end, not an announced results date. [#SEC-8K-2026-11-03]
Prob 55.00% • Move 12.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Q3 earnings reaction and revised outlook
2026-11-18
Clarivate reported Q3 adjusted EPS of $0.21, above the $0.18 pre-report estimate cited by Investing.com. Continuing-operations revenue fell 9.2% year over year, while organic recurring revenue rose 1.3%. Following the Life Sciences & Healthcare sale, management set Q4 revenue guidance of $490 million–$510 million. Shares closed November 3 at $2.09, up 25.9% from November 2; that sharp move limits the near-term opportunity. [#8-K-2026-11-03] [#SEC-8K-2026-11-03] https://www.investing.com/news/earnings/clarivate-earnings-beat-by-003-revenue-fell-short-of-estimates-4994431 https://stockanalysis.com/stocks/clvt/history/
Prob 75% • Move 5% • Priced-in 75%

Long-term Catalysts

Months to a year

Prove growth and deleveraging after the portfolio sale
2027-12-31
Clarivate completed the Life Sciences & Healthcare sale on October 6 for $488.4 million in net cash proceeds. Management expects its remaining Academia & Government and Intellectual Property businesses, including AI-led offerings, to support sustained organic growth and lower leverage. This remains a thesis to test, not a quantified product-sales forecast. [#SEC-8K-2026-11-03]
Prob 45% • Move 20% • Priced-in 30%

Risks

A 25.9% post-results close-to-close gain increases reversal risk. https://stockanalysis.com/stocks/clvt/history/
High debt and lower year-to-date free cash flow leave deleveraging dependent on execution. [#SEC-8K-2026-11-03]
Lower transactional activity and product wind-downs may offset subscription gains. [#SEC-8K-2026-11-03]
Q3 continuing-operations revenue declined 9.2% year over year despite modest organic growth. [#SEC-8K-2026-11-03]
The 2026 outlook reflects the divestiture; comparisons with pre-sale revenue consensus may mix continuing and discontinued operations. [#SEC-8K-2026-11-03]

Peers

Symbol	Summary
INOD	Packet-supplied, similar-market-cap data-services candidate, but not an established direct comparable for Clarivate's subscription research and IP franchises.
CRAI	Packet-supplied, similar-market-cap professional-services candidate; its business model is too different to anchor Clarivate valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-11-04

Loading AI feed…

Symbol

Summary

INOD

Packet-supplied, similar-market-cap data-services candidate, but not an established direct comparable for Clarivate's subscription research and IP franchises.

CRAI

Packet-supplied, similar-market-cap professional-services candidate; its business model is too different to anchor Clarivate valuation.